Pharmacogenomics, by extension, is the study of how pharmaceutical agents interact with the output of the human genome. In 1956, Arno Motulsky proposed genetic variation as an explanation for individual differences in drug efficacies and adverse reactions. The first pharmacogenomic association was demonstrated with the association of peripheral neuropathy in isoniazid âslow acetylatorsâ in 1960. Andrew A. Monte, Omics Screening for Pharmaceutical Efficacy and Safety in Clinical Practice.
Last date updated on November, 2020